Permissive Insta-star dies after cosmetic surgery

There is hope that one or more vaccines will be available very soon. “Then we can defeat the virus step by step.”

Due to delays in setting up the supply chain for the vaccine of the German company Biontech and the US pharmaceutical company Pfizer, there are fewer vaccine doses than expected in the first few weeks, as Federal Health Minister Jens Spahn (CDU) said in Berlin on Friday. If approval is granted, the first vaccinations in Germany can be expected at the turn of the year.

Spahn promised mass vaccinations by the summer. “As of today, I am very optimistic that there will be mass vaccinations by the summer at the latest,” he told the news portal t-online. He is assuming that it will then also be possible to vaccinate “nationwide” in doctors’ offices. When asked whether Germany was through with the worst in autumn, Spahn replied: “If as many as possible take advantage of the vaccination offer: yes.”

In total, there are five candidates for vaccine developments that with a “certain probability” would be approved by the middle of the year. In addition to the developments from Biontech / Pfizer and Moderna, Spahn also included products from Curevac, Astra Zeneca and Johnson Johnson. Millions of German citizens could already be immune from vaccinations in the spring. By the end of March, “11 million cans from Biontech alone are realistic for Germany”.

The German Foundation for Patient Protection warned against false hopes of a victory over the virus through the vaccinations. “It is important that as many people as possible get vaccinated,” said board member Eugen Brysch on Saturday of the German press agency. “This makes it easier to live with the virus.” The chances and goals of the vaccinations are clear: Much less severe disease and fewer people who die from and with the virus. “Simplifications will not get us any further in the public discussion in the vaccination campaign,” said Brysch. The federal government should beware of this. “Because even the message” Anyone who is vaccinated cannot contract Covid-19 and is immune “is not true,” said Brysch.

The coalition had stipulated by law that the federal government can establish the rules for corona vaccination by ordinance. Risk groups, i.e. the elderly and the sick, employees in the health service and in central areas of general interest, are already mentioned under this law. The German Ethics Council, the National Science Academy Leopoldina and the Standing Vaccination Commission at the Robert Koch Institute (RKI) had announced a finer definition of this prioritization for the period up to the end of the year.

According to a draft of the Scientific Services of the Bundestag, vaccination against the coronavirus by regulation is not the right way. The document available to the dpa states: “The prevailing view, according to which the prioritization of certain population groups with regard to access to vaccines requires a formal law that regulates at least the essential criteria for the distribution of a scarce vaccine, must be approved.”

Finally, the Federal Constitutional Court held that the relevance of a measure to fundamental rights was decisive for whether it should be regulated by a formal law. The possibility of being able to obtain vaccination protection against the cause of the disease Covid-19 is of enormous relevance for the entire population, since everyone is equally affected by the risk of infection and the resulting restrictions in everyday life, according to the draft of the FDP -Faction Vice Stephan Thomae had requested. Thomae warned that the Bundestag should not “be demoted to being just a spectator again”.

The draft of the Federal Ministry of Health for an “Ordinance on the right to vaccination against the Sars-CoV-2 coronavirus” is currently still being voted within the government.https://123helpme.me/community-service-essay/

Berlin (dpa) – After a rapid increase in October and the beginning of November, the number of reported new corona infections in Germany has leveled off at a high level.

T-Online.de/TV

Nursing home action causes a stir

Macron reports from quarantine with a video message

MPs reckon with sexism in the Bundestag

Trump casino is blown up – who can push the button?

Instagram star dies after cosmetic surgery

Elephant cow gives birth – reaction of the herd amazes

US Vice President Pence vaccinated against Corona

NASA mission enables a first look inside Mars

These rules apply to your fireworks in the garden

Spahn asks for patience when distributing the vaccine

Strange beer appearance in the US Parliament

Suddenly there is no stopping the minister

Container use due to Corona causes a stir

Towing service has a bad surprise

Winter weather causes chaos on the US east coast

The decline hoped for after the partial lockdown came into force has not yet been clearly identified, as is evident from Sunday’s figures from the Robert Koch Institute. The daily number of new infections reported by the RKI to the health authorities within seven days has fluctuated between around 115,000 and around 119,000 for two weeks. The seven-day incidence derived from this – i.e. the number of new infections per week and 100,000 inhabitants – was relatively stable over the same period at around 140, with only minor deviations upwards and downwards.

A partial lockdown has been in effect in Germany since the beginning of November, pubs and restaurants, for example, are closed.

Sauerland: Fatal accident in the sawmill: Employee trapped Podcast on IS: “New York Times” falls on impostors Breakdown series: Cosmonauts fight air leaks on the ISS From Biontech and Moderna: Germany is getting more vaccination doses than previously known

The value of new infections per week is comparatively good for reading trends in the infection process. Unlike the number of new infections reported within a day, it does not depend on the day of the week. In particular, the numbers reported by the RKI on Sundays and Mondays are comparatively low because fewer samples are taken on the weekend and therefore fewer tests are carried out overall.

On Sunday, the RKI reported a comparatively low number of new infections with 15,741 cases that were transmitted by the health authorities within 24 hours. On Sunday a week ago it was 16,947. The highest level since the pandemic began was reached on Friday with 23,648 reported cases.

According to data from the German Interdisciplinary Association for Intensive Care and Emergency Medicine, the number of corona patients in the intensive care unit continues to rise, but not as much recently.

Since the beginning of the pandemic, the RKI has counted a total of 918,269 detected infections with Sars-CoV-2 in Germany (as of November 22, 00:00). The number of deaths related to the virus rose 138 as of Sunday to a total of 14,022. The RKI estimates that around 603,800 people have now recovered.

According to the RKI situation report on Sunday, the so-called seven-day R was 1.03 (previous day: 1.07). This means that, on average, every person who is infected with SARS-CoV-2 infects approximately one more person. The value represents the occurrence of the infection 8 to 16 days ago. If it is below 1 for a long time, the infection process subsides.

Mainz / New York (dpa) – The Mainz company Biontech and the US pharmaceutical giant Pfizer have applied to the European Medicines Agency (Ema) for approval of their corona vaccine in the EU.

T-Online.de/TV

Nursing home action causes a stir

Macron reports from quarantine with a video message

MPs reckon with sexism in the Bundestag

Trump casino is blown up – who can push the button?

Permissive Insta-star dies after cosmetic surgery

Elephant cow gives birth – reaction of the herd amazes

US Vice President Pence vaccinated against Corona

NASA mission enables a first look inside Mars

These rules apply to your fireworks in the garden

Spahn asks for patience when distributing the vaccine

Strange beer appearance in the US Parliament

Suddenly there is no stopping the minister

Container use due to Corona causes a stir

Towing service has a bad surprise

Winter weather causes chaos on the US east coast

The application for a conditional marketing authorization was submitted on Monday, announced Biontech and Pfizer on Tuesday. On Monday, the US company Moderna also submitted a corresponding application for its vaccine to Ema.

Ema now has to check the applications. How long this would take was initially unclear. If the authority recommends conditional approval, the vaccine could still be used in December, said Biontech. The final decision is made by the EU Commission, which usually follows the Ema recommendation.

Biontech had announced that it would be able to start delivering the first vaccines immediately after approval. Biontech / Pfizer and Moderna have also filed for emergency approval with the US Food and Drug Administration.

For the Biontech / Pfizer vaccine with the designation BNT162b2, extensive test series showed an effectiveness that offers 95 percent protection against the disease Covid-19, according to the company. The vaccine works similarly well across all age groups and other demographic differences and shows practically no serious side effects, said the companies after the final analysis. The vaccination protection for people who are over 65 years old is over 94 percent.

These positive results relate to protection against Covid 19 disease. It is not yet clear to what extent the vaccine also protects against infection and possible transmission of the virus.

The vaccine from Biontech / Pfizer is comparatively similar to the preparation from Moderna in its mode of action and also in its effectiveness. A so-called rolling review process is already running at Ema for both vaccines, which is intended to accelerate the approval process. Manufacturers can submit individual parts on the quality, safety and effectiveness of a preparation even before the complete application for approval.

According to Biontech, the vaccine doses should be distributed “fairly”. The company announced that “one country would not get everything”. Germany and the EU have already signed a framework agreement for the purchase of up to 300 million doses of the vaccine. On the basis of delivery forecasts, Biontech assumes that up to 50 million vaccine doses will be shipped worldwide this year and up to 1.3 billion doses will be produced next year. The vaccination is given in two doses.

“As a company based in the heart of Europe, today’s milestone is immensely important to us as we continue to strive to enable worldwide distribution after the potential approval of BNT162b2,” said Biontech CEO and co-founder Ugur Sahin. “We intend to continue working with regulatory agencies around the world to enable rapid global distribution of our vaccine if approved. We would like to contribute to global efforts to fight the virus to get it back to normal.”

According to the information, Biontech and Pfizer have also submitted an application for approval to the British regulatory authority MHRA. There are also rolling proceedings in Australia, Canada and Japan, among others. Further applications worldwide are planned.

Last week, EU Commission chief Ursula von der Leyen announced that a framework contract for up to 160 million vaccine doses had been concluded with Moderna. Accordingly, 80 million cans are to be delivered initially, with the option of 80 million more units. According to Moderna, the product could be delivered in the EU as early as December, provided it receives approval.

The preparation from Pfizer and Biontech is, like that from Moderna, a so-called RNA vaccine. It contains genetic information about the pathogen, from which the body then produces a virus protein. The aim of vaccination is to stimulate the immune system to produce antibodies in order to intercept the viruses. There is still no approved vaccine of this type.

Countries such as Russia, China and recently Bahrain have already released vaccines with restrictions and are already vaccinating parts of the population with them. But how well these vaccinations actually protect and what side effects they can have is currently largely open.

Berlin (dpa) – Experts warn of dubious corona protection promises made by providers of means such as ginger extract and hemp oil.

Space station: air leaks: cosmonauts struggle with problems on the ISS Arianespace project: satellites brought into space for fast internet Cause of crash found: Arianespace wants to launch Vega rocket again after crash. Unpleasant but harmless? than a million obstacles divide Europe’s rivers

“Among the dietary supplements there are no miracle cures against Covid-19”, emphasized Friedel Cramer, President of the Federal Office for Consumer Protection and Food Safety (BVL), in Berlin. “In my opinion it is unheard of how some traders are trying to profit from people’s fears in the current situation.” Dietary supplements could neither prevent nor cure Covid-19 diseases. Nor should they be advertised with statements related to illness. 

In Germany, the control bodies of the federal states have already found 60 such offers on the Internet. In the course of a Europe-wide control campaign, 592 suspicious websites have been identified so far. According to the BVL, the German-language offers were forwarded to the responsible supervisory authorities for review. After controls, the offers were changed or deleted.

T-Online.de/TV

Influencer (30) dies in butt lift

Elephant cow gives birth – reaction of the herd amazes

US Vice President Pence vaccinated against Corona

NASA mission enables a first look inside Mars

These rules apply to your fireworks in the garden

Spahn asks for patience when distributing the vaccine

Strange beer appearance in the US Parliament

Suddenly there is no stopping the minister

Container use due to Corona causes a stir

Towing service has a bad surprise

Winter weather causes chaos on the US east coast

What are the chances of a white Christmas?

Santa Claus approaches with a sledgehammer

Hunter discovers lynx – and records exciting scene

Why the situation in Saxony is getting worse

Consumer advice centers have been warning of dubious providers for a long time and are taking action. “More and more manufacturers are promoting their dietary supplements or plant extracts with alleged protection against infection with the coronavirus